Evidence map›Paper›PMID 27466816›Full record

ArticlePloS one2016

Immune Recognition of Citrullinated Proteoglycan Aggrecan Epitopes in Mice with Proteoglycan-Induced Arthritis and in Patients with Rheumatoid Arthritis.

Adrienn Markovics, Tímea Ocskó, Robert S Katz, Edit I Buzás, Tibor T Glant, Katalin Mikecz

Open access · goldAbstract readValidation Study
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. C-type lectins in immunity and homeostasis.Nature reviews. Immunology · 2018
    Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Adrienn MarkovicsSection of Molecular Medicine, Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, United States of America.
Tímea OcskóSection of Molecular Medicine, Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, United States of America.
Robert S KatzRheumatology Associates, Rush University Medical Center, Chicago, Illinois, United States of America.
Edit I BuzásDepartment of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary.
Tibor T GlantSection of Molecular Medicine, Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, United States of America.
Katalin MikeczSection of Molecular Medicine, Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, United States of America.ORCID http://orcid.org/0000-0003-1506-4296
Rush University Medical Center · USSemmelweis University · HU

Funding

Mapping of Arthritis Susceptibility GenesR01AR059356 · NIAMS · RUSH UNIVERSITY MEDICAL CENTER · PI GLANT, TIBOR T. · 2010 to 2014
$2.2M
Immune Recognition of Citrullinated Cartilage PG Aggrecan in Autoimmune ArthritisR01AR064206 · NIAMS · RUSH UNIVERSITY MEDICAL CENTER · PI MIKECZ, KATALIN · 2013 to 2017
$1.6M
NIAMS NIH HHS R01 AR059356NIAMS NIH HHS R01 AR064206
6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is an autoimmune inflammatory disease affecting the joints. Anti-citrullinated protein antibodies (ACPA) are frequently found in RA. Previous studies identified a citrullinated epitope in cartilage proteoglycan (PG) aggrecan that elicited pro-inflammatory cytokine production by RA T cells. We recently reported the presence of ACPA-reactive (citrullinated) PG in RA cartilage. Herein, we sought to identify additional citrullinated epitopes in human PG that are recognized by T cells or antibodies from RA patients.

methodsWe used mice with PG-induced arthritis (PGIA) as a screening tool to select citrulline (Cit)-containing PG peptides that were more immunogenic than the arginine (R)-containing counterparts. The selected peptide pairs were tested for induction of pro-inflammatory T-cell cytokine production in RA and healthy control peripheral blood mononuclear cell (PBMC) cultures using ELISA and flow cytometry. Anti-Cit and anti-R peptide antibodies were detected by ELISA.

resultsSplenocytes from mice with PGIA exhibited greater T-cell cytokine secretion in response to the Cit than the R version of PG peptide 49 (P49) and anti-P49 antibodies were found in PGIA serum. PBMC from ACPA+ and ACPA- RA patients, but not from healthy controls, responded to Cit49 with robust cytokine production. High levels of anti-Cit49 antibodies were found in the plasma of a subset of ACPA+ RA patients. Another PG peptide (Cit13) similar to the previously described T-cell epitope induced greater cytokine responses than R13 by control (but not RA) PBMC, however, anti-Cit13 antibodies were rarely detected in human plasma.

conclusionsWe identified a novel citrullinated PG epitope (Cit49) that is highly immunogenic in mice with PGIA and in RA patients. We also describe T-cell and antibody reactivity with Cit49 in ACPA+ RA. As citrullinated PG might be present in RA articular cartilage, Cit PG epitope-induced T-cell activation or antibody deposition may occur in the joints of RA patients.

Indexed as

AggrecansAmino Acid SequenceAnimalsArthritis, ExperimentalArthritis, RheumatoidB-LymphocytesCase-Control StudiesCell ProliferationCells, CulturedCitrullineCytokinesEnzyme-Linked Immunosorbent AssayEpitopesFlow CytometryHumansMiceAggrecansCitrullineCytokinesEpitopesProteoglycans

Identifiers

PMID27466816
PMCPMC4965111
OpenAlexW2486272166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.